Natural Alternatives International, Inc. Announces Fiscal 2027 Q1 Results
11/15/2026
Impact: -62
Consumer Defensive
Natural Alternatives International reported fiscal 2027 first-quarter net sales of $28.1 million, down 25.5% from $37.7 million a year earlier, and a net loss of $2.5 million, or $0.41 per diluted share, compared with a $0.3 million loss, or $0.05 per share. Private-label contract manufacturing sales fell 29.1%, as several large customers reduced orders amid excess inventory and delayed product launches; new customer launches partly offset the decline. CarnoSyn beta-alanine royalty, licensing, and raw-material revenue rose 54.0% to $2.6 million, driven by higher TriBsyn sales.
AI summary, not financial advice
Share: